Abstract
Osteosarcoma is the most common primary bone malignancy of adolescents and young adults. Existing treatment options and surgical intervention are unable to effectively manage this tumor. Therefore, novel mechanism-based targets and strategies need to be rationally established to strive for improvement in the survival of patients diagnosed with osteosarcoma. The serine/threonine kinases Polo-like kinase (Plk) 1 is a key regulator of cell division in eukaryotic cells. Plk1 gene and protein expression has been proposed as a new prognostic marker for many types of malignancies, and Plk1 is a potential target for cancer therapy. In this review, we shall discuss the studies which indicate that Plk1 could be an excellent target for the treatment of osteosarcoma.
Keywords: Plk1, osteosarcoma, cancer, therapy, target.
Current Pharmaceutical Design
Title:Polo-Like Kinase 1 as a Potential Therapeutic Target for Osteosarcoma
Volume: 21 Issue: 10
Author(s): Li Cheng, Chongchong Wang and Juehua Jing
Affiliation:
Keywords: Plk1, osteosarcoma, cancer, therapy, target.
Abstract: Osteosarcoma is the most common primary bone malignancy of adolescents and young adults. Existing treatment options and surgical intervention are unable to effectively manage this tumor. Therefore, novel mechanism-based targets and strategies need to be rationally established to strive for improvement in the survival of patients diagnosed with osteosarcoma. The serine/threonine kinases Polo-like kinase (Plk) 1 is a key regulator of cell division in eukaryotic cells. Plk1 gene and protein expression has been proposed as a new prognostic marker for many types of malignancies, and Plk1 is a potential target for cancer therapy. In this review, we shall discuss the studies which indicate that Plk1 could be an excellent target for the treatment of osteosarcoma.
Export Options
About this article
Cite this article as:
Cheng Li, Wang Chongchong and Jing Juehua, Polo-Like Kinase 1 as a Potential Therapeutic Target for Osteosarcoma, Current Pharmaceutical Design 2015; 21 (10) . https://dx.doi.org/10.2174/1381612820999141029162811
DOI https://dx.doi.org/10.2174/1381612820999141029162811 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
FADS1 is a Prognostic Biomarker in Bladder Cancer: A Study Based on TCGA Data
Combinatorial Chemistry & High Throughput Screening Pharmacological Intervention of Cyclooxygenase-2 and 5-Lipoxygenase Pathways. Impact on Inflammation and Cancer
Current Pharmaceutical Design Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry Fluid-fluid Levels in Musculoskeletal Tumor Imaging
Current Medical Imaging Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research The Re-Emergence of Aerosol Gene Delivery: A Viable Approach to Lung Cancer Therapy
Current Cancer Drug Targets Alpha-Particle Microdosimetry
Current Radiopharmaceuticals Quinones Derived from Plant Secondary Metabolites as Anti-cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Radiobromine-Labelled Tracers for Positron Emission Tomography: Possibilities and Pitfalls
Current Radiopharmaceuticals TWIST1 Gene: First Insights in Felis catus
Current Genomics Piper Sarmentosum: A New Hope for the Treatment of Osteoporosis
Current Drug Targets Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Current Genomics Potential Use of Vanadium Compounds in Therapeutics
Current Medicinal Chemistry Emerging Features in the Regulation of MMP-9 Gene Expression for the Development of Novel Molecular Targets and Therapeutic Strategies
Current Drug Targets - Inflammation & Allergy Double Layered Hydroxides as Potential Anti-Cancer Drug Delivery Agents
Mini-Reviews in Medicinal Chemistry Genome and Transcriptome Analysis of Neuroblastoma Advanced Diagnosis from Innovative Therapies
Current Pharmaceutical Design Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued) Novel Anticancer Strategy Aimed at Targeting Shelterin Complexes by the Induction of Structural Changes in Telomeric DNA: Hitting two Birds with one Stone
Current Cancer Drug Targets MiR-22-3p Regulates Amyloid β Deposit in Mice Model of Alzheimer's Disease by Targeting Mitogen-activated Protein Kinase 14
Current Neurovascular Research MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs
Current Drug Targets